查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1772236

全球 Rozanolixizumab（Rystiggo）市场：市场规模、份额、趋势分析（按适应症、分销管道和地区）、细分市场预测（2025-2033）

Rozanolixizumab (Rystiggo) Market Size, Share & Trends Analysis Report By Indication (Generalized Myasthenia Gravis (gMG), Emerging Pipeline Applications), By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2033
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10个工作天内

价格

Rozanolixizumab (Rystiggo) 市场摘要

2024 年全球 Rozanolixizumab (Rystiggo) 市场规模估计为 2.1861 亿美元，预计到 2033 年将达到 17.004 亿美元，2025 年至 2033 年的复合年增长率为 15.22%。慢性寻常性干癣和银屑病关节炎盛行率的不断上升推动了对先进生物製药的需求。

重症全身性肌无力 (gMG) 的核准推动了市场发展。国际趋势包括标靶治疗药物需求的不断增长以及全球监管部门的核准，这主要得益于核准可能性的提高和医疗资源的增加。优时比 (UCB) 的创新方法和新兴产品线支撑了市场成长。罗扎诺利珠单抗 (Rystiggo) 市场针对的是 gMG，一种慢性自体免疫免疫疾病，其盛行率的上升正在推动需求成长。 Rystiggo 已在美国和欧洲核准，可皮下注射，并能有效降低 IgG 抗体，从而刺激了该药物的推广。市场成长的驱动力在于诊断率的上升以及人口老化，后者更容易患上自体免疫疾病。优时比致力于扩大其适应症，预计到 2033 年，适应症将进一步增加。

Rystiggo 的主要优势在于其创新的 FcRn 标靶机制，可显着改善吞嚥和呼吸等重症肌无力 (gMG) 症状，已在 MycarinG 研究中得到证实。与血浆置换相比，Rystiggo 可在维持疗效的同时减少副作用。皮下给药提高了患者的便利性，使其在静脉注射治疗中占据优势。

新兴创新包括慢性发炎去髓鞘化综合症 (CIDP) 检测和自我给药。成功的产品线扩展预计将使潜在市场到 2033 年翻倍。给药系统的进步旨在提高依从性，而生物相似药的潜力可能带来竞争，同时在长期内平衡成本和可近性。

目录

第一章 分析方法与范围

第二章执行摘要

3. Rozanolixizumab（Rystiggo）市场：变数、趋势与范围

  • 市场联动展望
    • 母市场展望
    • 相关/附随市场展望
  • 市场动态
    • 市场驱动因素分析
    • 市场限制分析
  • 商业环境分析
    • 产业分析：波特五力分析
    • PESTEL分析
    • 管道分析
    • 专利到期分析
    • 定价分析

4. Rozanolixizumab（Rystiggo）市场：按适应症进行的商业分析

  • 各适应症市场占有率（2024 年及 2033 年）
  • 细分仪表板：依指示
  • 市场规模预测及趋势分析（2021-2033）
  • 全身性重症肌无力（gMG）
  • 其他的

第五章 Rozanolixizumab（Rystiggo）市场：通路业务分析

  • 按分销管道分類的市场占有率（2024 年和 2033 年）
  • 细分仪表板：按分销管道
  • 按分销管道分類的市场规模预测和趋势分析（2021-2033 年）
  • 医院和专科药房
  • 零售与电子商务

第六章 Rozanolixizumab（Rystiggo）市场：按地区估计和趋势分析

  • 各地区市场占有率（2024 年及 2033 年）
  • 市场仪表板：按地区
  • 各地区市场规模预测及趋势分析（2021-2033）
  • 北美洲
    • 按国家/地区（2021-2033 年）
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 丹麦
    • 瑞典
    • 挪威
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 韩国
    • 泰国
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中东和非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第七章 竞争态势

  • 参与企业概况
  • 企业市场分析
  • 公司分类
  • 战略地图
  • 公司简介/上市公司
    • UCB
Product Code: GVR-4-68040-644-4

Rozanolixizumab (Rystiggo) Market Summary

The global rozanolixizumab (Rystiggo) market size was estimated at USD 218.61 million in 2024 and is projected to reach USD 1,700.40 million by 2033, growing at a CAGR of 15.22% from 2025 to 2033. The increasing prevalence of chronic plaque psoriasis and psoriatic arthritis drives greater demand for advanced biologic therapies.

The market is driven by its approval for generalized myasthenia gravis (gMG). Key trends include rising demand for targeted therapies and global regulatory approvals, fueled by potential approvals and increasing healthcare access. Growth is supported by UCB's innovative approach and emerging pipeline applications. The rozanolixizumab (Rystiggo) market targets gMG, a chronic autoimmune disorder, with growing prevalence driving demand. Approved in the U.S. and Europe, Rystiggo's subcutaneous administration and efficacy in reducing IgG antibodies fuel its adoption. Market growth is propelled by rising diagnosis rates and an aging population susceptible to autoimmune diseases. UCB's focus on expanding indications further supports the projected increase by 2033.

Rystiggo's key advantage lies in its novel FcRn-targeting mechanism, offering significant improvements in gMG symptoms like swallowing and breathing, as demonstrated in the MycarinG study. Compared to plasma exchange, it reduces side effects while maintaining efficacy. Its subcutaneous delivery enhances patient convenience, positioning it favorably against intravenous competitors.

Emerging innovations include trials for chronic inflammatory demyelinating syndrome (CIDP) and self-administration methods. Successful pipeline expansion could double the addressable market by 2033. Advances in delivery systems aim to improve compliance, while potential biosimilars may introduce competition, balancing cost and accessibility in the long term.

Global Rozanolixizumab (Rystiggo) Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global rozanolixizumab (Rystiggo) market report based on indication, distribution channel and region:

  • Indication Outlook (Revenue, USD Million, 2021 - 2033)
  • Generalized Myasthenia Gravis (gMG)
  • Others
  • Distribution Channel Outlook (Revenue, USD Million, 2021 - 2033)
  • Hospital & Specialty Pharmacies
  • Retail & E Commerce
  • Regional Outlook (Revenue, USD Million, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Indication
    • 1.2.2. Distribution Channel
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Rozanolixizumab (Rystiggo) Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrants
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTLE Analysis
    • 3.3.3. Pipeline Analysis
    • 3.3.4. Patent Expiry Analysis
    • 3.3.5. Pricing Analysis

Chapter 4. Rozanolixizumab (Rystiggo) Market: Indication Business Analysis

  • 4.1. Indication Market Share, 2024 & 2033
  • 4.2. Indication Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Indication, 2021 to 2033 (USD Million)
  • 4.4. Generalized Myasthenia Gravis (gMG)
    • 4.4.1. Generalized Myasthenia Gravis (gMG) Market, 2021 - 2033 (USD Million)
  • 4.5. Others
    • 4.5.1. Others Market, 2021 - 2033 (USD Million)

Chapter 5. Rozanolixizumab (Rystiggo) Market: Distribution Channel Business Analysis

  • 5.1. Distribution Channel Market Share, 2024 & 2033
  • 5.2. Distribution Channel Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, by Distribution Channel, 2021 to 2033 (USD Million)
  • 5.4. Hospital & Specialty Pharmacies
    • 5.4.1. Hospital & Specialty Pharmacies Market, 2021 - 2033 (USD Million)
  • 5.5. Retail & E-Commerce
    • 5.5.1. Retail & E-Commerce Market, 2021 - 2033 (USD Million)

Chapter 6. Rozanolixizumab (Rystiggo) Market: Regional Estimates & Trend Analysis

  • 6.1. Regional Market Share Analysis, 2024 & 2033
  • 6.2. Regional Market Dashboard
  • 6.3. Market Size & Forecasts Trend Analysis, 2021 to 2033:
  • 6.4. North America
    • 6.4.1. North America Rozanolixizumab (Rystiggo) Market Estimates And Forecasts, By Country, 2021 - 2033 (USD Million)
    • 6.4.2. U.S.
      • 6.4.2.1. Key Country Dynamics
      • 6.4.2.2. Target Disease Prevalence
      • 6.4.2.3. Regulatory Framework
      • 6.4.2.4. Reimbursement Framework
      • 6.4.2.5. U.S. Rozanolixizumab (Rystiggo) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.4.3. Canada
      • 6.4.3.1. Key Country Dynamics
      • 6.4.3.2. Target Disease Prevalence
      • 6.4.3.3. Regulatory Framework
      • 6.4.3.4. Reimbursement Framework
      • 6.4.3.5. U.S. Rozanolixizumab (Rystiggo) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.4.4. Mexico
      • 6.4.4.1. Key Country Dynamics
      • 6.4.4.2. Target Disease Prevalence
      • 6.4.4.3. Regulatory Framework
      • 6.4.4.4. Reimbursement Framework
      • 6.4.4.5. Mexico Rozanolixizumab (Rystiggo) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5. Europe
    • 6.5.1. Europe Rozanolixizumab (Rystiggo) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.2. UK
      • 6.5.2.1. Key Country Dynamics
      • 6.5.2.2. Target Disease Prevalence
      • 6.5.2.3. Regulatory Framework
      • 6.5.2.4. Reimbursement Framework
      • 6.5.2.5. Uk Rozanolixizumab (Rystiggo) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.3. Germany
      • 6.5.3.1. Key Country Dynamics
      • 6.5.3.2. Target Disease Prevalence
      • 6.5.3.3. Regulatory Framework
      • 6.5.3.4. Reimbursement Framework
      • 6.5.3.5. Germany Rozanolixizumab (Rystiggo) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.4. France
      • 6.5.4.1. Key Country Dynamics
      • 6.5.4.2. Target Disease Prevalence
      • 6.5.4.3. Regulatory Framework
      • 6.5.4.4. Reimbursement Framework
      • 6.5.4.5. France Rozanolixizumab (Rystiggo) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.5. Italy
      • 6.5.5.1. Key Country Dynamics
      • 6.5.5.2. Target Disease Prevalence
      • 6.5.5.3. Regulatory Framework
      • 6.5.5.4. Reimbursement Framework
      • 6.5.5.5. Italy Rozanolixizumab (Rystiggo) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.6. Spain
      • 6.5.6.1. Key Country Dynamics
      • 6.5.6.2. Target Disease Prevalence
      • 6.5.6.3. Regulatory Framework
      • 6.5.6.4. Reimbursement Framework
      • 6.5.6.5. Spain Rozanolixizumab (Rystiggo) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.7. Denmark
      • 6.5.7.1. Key Country Dynamics
      • 6.5.7.2. Target Disease Prevalence
      • 6.5.7.3. Regulatory Framework
      • 6.5.7.4. Reimbursement Framework
      • 6.5.7.5. Denmark Rozanolixizumab (Rystiggo) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.8. Sweden
      • 6.5.8.1. Key Country Dynamics
      • 6.5.8.2. Target Disease Prevalence
      • 6.5.8.3. Regulatory Framework
      • 6.5.8.4. Reimbursement Framework
      • 6.5.8.5. Sweden Rozanolixizumab (Rystiggo) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.9. Norway
      • 6.5.9.1. Key Country Dynamics
      • 6.5.9.2. Target Disease Prevalence
      • 6.5.9.3. Regulatory Framework
      • 6.5.9.4. Reimbursement Framework
      • 6.5.9.5. Norway Rozanolixizumab (Rystiggo) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.6. Asia Pacific
    • 6.6.1. Asia Pacific Rozanolixizumab (Rystiggo) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.2. Japan
      • 6.6.2.1. Key Country Dynamics
      • 6.6.2.2. Target Disease Prevalence
      • 6.6.2.3. Regulatory Framework
      • 6.6.2.4. Reimbursement Framework
      • 6.6.2.5. Japan Rozanolixizumab (Rystiggo) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.3. China
      • 6.6.3.1. Key Country Dynamics
      • 6.6.3.2. Target Disease Prevalence
      • 6.6.3.3. Regulatory Framework
      • 6.6.3.4. Reimbursement Framework
      • 6.6.3.5. China Rozanolixizumab (Rystiggo) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.4. India
      • 6.6.4.1. Key Country Dynamics
      • 6.6.4.2. Target Disease Prevalence
      • 6.6.4.3. Regulatory Framework
      • 6.6.4.4. Reimbursement Framework
      • 6.6.4.5. India Rozanolixizumab (Rystiggo) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.5. Australia
      • 6.6.5.1. Key Country Dynamics
      • 6.6.5.2. Target Disease Prevalence
      • 6.6.5.3. Regulatory Framework
      • 6.6.5.4. Reimbursement Framework
      • 6.6.5.5. Australia Rozanolixizumab (Rystiggo) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.6. South Korea
      • 6.6.6.1. Key Country Dynamics
      • 6.6.6.2. Target Disease Prevalence
      • 6.6.6.3. Regulatory Framework
      • 6.6.6.4. Reimbursement Framework
      • 6.6.6.5. South Korea Rozanolixizumab (Rystiggo) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.7. Thailand
      • 6.6.7.1. Key Country Dynamics
      • 6.6.7.2. Target Disease Prevalence
      • 6.6.7.3. Regulatory Framework
      • 6.6.7.4. Reimbursement Framework
      • 6.6.7.5. Thailand Rozanolixizumab (Rystiggo) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.7. Latin America
    • 6.7.1. Latin America Rozanolixizumab (Rystiggo) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.7.2. Brazil
      • 6.7.2.1. Key Country Dynamics
      • 6.7.2.2. Target Disease Prevalence
      • 6.7.2.3. Regulatory Framework
      • 6.7.2.4. Reimbursement Framework
      • 6.7.2.5. Japan Rozanolixizumab (Rystiggo) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.7.3. Argentina
      • 6.7.3.1. Key Country Dynamics
      • 6.7.3.2. Target Disease Prevalence
      • 6.7.3.3. Regulatory Framework
      • 6.7.3.4. Reimbursement Framework
      • 6.7.3.5. China Rozanolixizumab (Rystiggo) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.8. Middle East and Africa
    • 6.8.1. Middle East and Africa Rozanolixizumab (Rystiggo) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.8.2. South Africa
      • 6.8.2.1. Key Country Dynamics
      • 6.8.2.2. Target Disease Prevalence
      • 6.8.2.3. Regulatory Framework
      • 6.8.2.4. Reimbursement Framework
      • 6.8.2.5. South Africa Rozanolixizumab (Rystiggo) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.8.3. Saudi Arabia
      • 6.8.3.1. Key Country Dynamics
      • 6.8.3.2. Target Disease Prevalence
      • 6.8.3.3. Regulatory Framework
      • 6.8.3.4. Reimbursement Framework
      • 6.8.3.5. Saudi Arabia Rozanolixizumab (Rystiggo) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.8.4. UAE
      • 6.8.4.1. Key Country Dynamics
      • 6.8.4.2. Target Disease Prevalence
      • 6.8.4.3. Regulatory Framework
      • 6.8.4.4. Reimbursement Framework
      • 6.8.4.5. UAE Rozanolixizumab (Rystiggo) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.8.5. Kuwait
      • 6.8.5.1. Key Country Dynamics
      • 6.8.5.2. Target Disease Prevalence
      • 6.8.5.3. Regulatory Framework
      • 6.8.5.4. Reimbursement Framework
      • 6.8.5.5. Kuwait Rozanolixizumab (Rystiggo) Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Participant Overview
  • 7.2. Company Market Position Analysis
  • 7.3. Company Categorization
  • 7.4. Strategy Mapping
  • 7.5. Company Profiles/Listing
    • 7.5.1. UCB
      • 7.5.1.1. Overview
      • 7.5.1.2. Financial Performance
      • 7.5.1.3. Product Benchmarking
      • 7.5.1.4. Strategic Initiatives

List of Tables

  • Table 1. List of secondary sources
  • Table 2. List of abbreviations
  • Table 3. Global Rozanolixizumab (Rystiggo) market, by region, 2021 - 2033 (USD Million)
  • Table 4. Global Rozanolixizumab (Rystiggo) market, by indication, 2021 - 2033 (USD Million)
  • Table 5. Global Rozanolixizumab (Rystiggo) market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 6. North America Rozanolixizumab (Rystiggo) market, by country, 2021 - 2033 (USD Million)
  • Table 7. North America Rozanolixizumab (Rystiggo) market, by indication, 2021 - 2033 (USD Million)
  • Table 8. North America Rozanolixizumab (Rystiggo) market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 9. U.S. Rozanolixizumab (Rystiggo) market, by indication, 2021 - 2033 (USD Million)
  • Table 10. U.S. Rozanolixizumab (Rystiggo) market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 11. Canada Rozanolixizumab (Rystiggo) market, by indication, 2021 - 2033 (USD Million)
  • Table 12. Canada Rozanolixizumab (Rystiggo) market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 13. Mexico Rozanolixizumab (Rystiggo) market, by indication, 2021 - 2033 (USD Million)
  • Table 14. Mexico Rozanolixizumab (Rystiggo) market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 15. Europe Rozanolixizumab (Rystiggo) market, by country, 2021 - 2033 (USD Million)
  • Table 16. Europe Rozanolixizumab (Rystiggo) market, by indication, 2021 - 2033 (USD Million)
  • Table 17. Europe Rozanolixizumab (Rystiggo) market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 18. UK Rozanolixizumab (Rystiggo) market, by indication, 2021 - 2033 (USD Million)
  • Table 19. UK Rozanolixizumab (Rystiggo) market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 20. Germany Rozanolixizumab (Rystiggo) market, by indication, 2021 - 2033 (USD Million)
  • Table 21. Germany Rozanolixizumab (Rystiggo) market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 22. France Rozanolixizumab (Rystiggo) market, by indication, 2021 - 2033 (USD Million)
  • Table 23. France Rozanolixizumab (Rystiggo) market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 24. Italy Rozanolixizumab (Rystiggo) market, by indication, 2021 - 2033 (USD Million)
  • Table 25. Italy Rozanolixizumab (Rystiggo) market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 26. Spain Rozanolixizumab (Rystiggo) market, by indication, 2021 - 2033 (USD Million)
  • Table 27. Spain Rozanolixizumab (Rystiggo) market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 28. Norway Rozanolixizumab (Rystiggo) market, by indication, 2021 - 2033 (USD Million)
  • Table 29. Norway Rozanolixizumab (Rystiggo) market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 30. Denmark Rozanolixizumab (Rystiggo) market, by indication, 2021 - 2033 (USD Million)
  • Table 31. Denmark Rozanolixizumab (Rystiggo) market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 32. Sweden Rozanolixizumab (Rystiggo) market, by indication, 2021 - 2033 (USD Million)
  • Table 33. Sweden Rozanolixizumab (Rystiggo) market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 34. Asia Pacific Rozanolixizumab (Rystiggo) market, by country, 2021 - 2033 (USD Million)
  • Table 35. Asia Pacific Rozanolixizumab (Rystiggo) market, by indication, 2021 - 2033 (USD Million)
  • Table 36. Asia Pacific Rozanolixizumab (Rystiggo) market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 37. Japan Rozanolixizumab (Rystiggo) market, by indication, 2021 - 2033 (USD Million)
  • Table 38. Japan Rozanolixizumab (Rystiggo) market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 39. China Rozanolixizumab (Rystiggo) market, by indication, 2021 - 2033 (USD Million)
  • Table 40. China Rozanolixizumab (Rystiggo) market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 41. India Rozanolixizumab (Rystiggo) market, by indication, 2021 - 2033 (USD Million)
  • Table 42. India Rozanolixizumab (Rystiggo) market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 43. Australia Rozanolixizumab (Rystiggo) market, by indication, 2021 - 2033 (USD Million)
  • Table 44. Australia Rozanolixizumab (Rystiggo) market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 45. South Korea Rozanolixizumab (Rystiggo) market, by indication, 2021 - 2033 (USD Million)
  • Table 46. South Korea Rozanolixizumab (Rystiggo) market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 47. Thailand Rozanolixizumab (Rystiggo) market, by indication, 2021 - 2033 (USD Million)
  • Table 48. Thailand Rozanolixizumab (Rystiggo) market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 49. Latin America Rozanolixizumab (Rystiggo) market, by country, 2021 - 2033 (USD Million)
  • Table 50. Latin America Rozanolixizumab (Rystiggo) market, by indication, 2021 - 2033 (USD Million)
  • Table 51. Latin America Rozanolixizumab (Rystiggo) market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 52. Brazil Rozanolixizumab (Rystiggo) market, by indication, 2021 - 2033 (USD Million)
  • Table 53. Brazil Rozanolixizumab (Rystiggo) market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 54. Argentina Rozanolixizumab (Rystiggo) market, by indication, 2021 - 2033 (USD Million)
  • Table 55. Argentina Rozanolixizumab (Rystiggo) market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 56. Middle East & Africa Rozanolixizumab (Rystiggo) market, by country, 2021 - 2033 (USD Million)
  • Table 57. Middle East & Africa Rozanolixizumab (Rystiggo) market, by indication, 2021 - 2033 (USD Million)
  • Table 58. Middle East & Africa Rozanolixizumab (Rystiggo) market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 59. South Africa Rozanolixizumab (Rystiggo) market, by indication, 2021 - 2033 (USD Million)
  • Table 60. South Africa Rozanolixizumab (Rystiggo) market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 61. Saudi Arabia Rozanolixizumab (Rystiggo) market, by indication, 2021 - 2033 (USD Million)
  • Table 62. Saudi Arabia Rozanolixizumab (Rystiggo) market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 63. UAE Rozanolixizumab (Rystiggo) market, by indication, 2021 - 2033 (USD Million)
  • Table 64. UAE Rozanolixizumab (Rystiggo) market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 65. Kuwait Rozanolixizumab (Rystiggo) market, by indication, 2021 - 2033 (USD Million)
  • Table 66. Kuwait Rozanolixizumab (Rystiggo) market, by distribution channel, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Rozanolixizumab (Rystiggo) market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Therapeutic approach and application outlook (USD Million)
  • Fig. 10 Competitive landscape
  • Fig. 11 Rozanolixizumab (Rystiggo) market dynamics
  • Fig. 12 Rozanolixizumab (Rystiggo) market: Porter's five forces analysis
  • Fig. 13 Rozanolixizumab (Rystiggo) market: PESTLE analysis
  • Fig. 14 Indication market, 2021 - 2033 (USD Million)
  • Fig. 15 Generalized Myasthenia Gravis (gMG) market, 2021 - 2033 (USD Million)
  • Fig. 16 Emerging Pipeline Applications market, 2021 - 2033 (USD Million)
  • Fig. 17 Distribution Channel market, 2021 - 2033 (USD Million)
  • Fig. 18 Hospital & Specialty Pharmacies market, 2021 - 2033 (USD Million)
  • Fig. 19 Retail & E-Commerce market, 2021 - 2033 (USD Million)
  • Fig. 20 Rozanolixizumab (Rystiggo) market revenue, by region
  • Fig. 21 Regional marketplace: Key takeaways
  • Fig. 22 North America Rozanolixizumab (Rystiggo) market, 2021 - 2033 (USD Million)
  • Fig. 23 U.S. country dynamics
  • Fig. 24 U.S. Rozanolixizumab (Rystiggo) market, 2021 - 2033 (USD Million)
  • Fig. 25 Canada country dynamics
  • Fig. 26 Canada Rozanolixizumab (Rystiggo) market, 2021 - 2033 (USD Million)
  • Fig. 27 Mexico country dynamics
  • Fig. 28 Mexico Rozanolixizumab (Rystiggo) market, 2021 - 2033 (USD Million)
  • Fig. 29 Europe Rozanolixizumab (Rystiggo) market, 2021 - 2033 (USD Million)
  • Fig. 30 UK country dynamics
  • Fig. 31 UK Rozanolixizumab (Rystiggo) market, 2021 - 2033 (USD Million)
  • Fig. 32 Germany country dynamics
  • Fig. 33 Germany Rozanolixizumab (Rystiggo) market, 2021 - 2033 (USD Million)
  • Fig. 34 France country dynamics
  • Fig. 35 France Rozanolixizumab (Rystiggo) market, 2021 - 2033 (USD Million)
  • Fig. 36 Italy country dynamics
  • Fig. 37 Italy Rozanolixizumab (Rystiggo) market, 2021 - 2033 (USD Million)
  • Fig. 38 Spain country dynamics
  • Fig. 39 Spain Rozanolixizumab (Rystiggo) market, 2021 - 2033 (USD Million)
  • Fig. 40 Norway country dynamics
  • Fig. 41 Norway Rozanolixizumab (Rystiggo) market, 2021 - 2033 (USD Million)
  • Fig. 42 Sweden country dynamics
  • Fig. 43 Sweden Rozanolixizumab (Rystiggo) market, 2021 - 2033 (USD Million)
  • Fig. 44 Denmark country dynamics
  • Fig. 45 Denmark Rozanolixizumab (Rystiggo) market, 2021 - 2033 (USD Million)
  • Fig. 46 Asia Pacific Rozanolixizumab (Rystiggo) market, 2021 - 2033 (USD Million)
  • Fig. 47 Japan country dynamics
  • Fig. 48 Japan Rozanolixizumab (Rystiggo) market, 2021 - 2033 (USD Million)
  • Fig. 49 China country dynamics
  • Fig. 50 China Rozanolixizumab (Rystiggo) market, 2021 - 2033 (USD Million)
  • Fig. 51 India country dynamics
  • Fig. 52 India Rozanolixizumab (Rystiggo) market, 2021 - 2033 (USD Million)
  • Fig. 53 Australia country dynamics
  • Fig. 54 Australia Rozanolixizumab (Rystiggo) market, 2021 - 2033 (USD Million)
  • Fig. 55 South Korea country dynamics
  • Fig. 56 South Korea Rozanolixizumab (Rystiggo) market, 2021 - 2033 (USD Million)
  • Fig. 57 Thailand country dynamics
  • Fig. 58 Thailand Rozanolixizumab (Rystiggo) market, 2021 - 2033 (USD Million)
  • Fig. 59 Latin America Rozanolixizumab (Rystiggo) market, 2021 - 2033 (USD Million)
  • Fig. 60 Brazil country dynamics
  • Fig. 61 Brazil Rozanolixizumab (Rystiggo) market, 2021 - 2033 (USD Million)
  • Fig. 62 Argentina country dynamics
  • Fig. 63 Argentina Rozanolixizumab (Rystiggo) market, 2021 - 2033 (USD Million)
  • Fig. 64 MEA Rozanolixizumab (Rystiggo) market, 2021 - 2033 (USD Million)
  • Fig. 65 South Africa country dynamics
  • Fig. 66 South Africa Rozanolixizumab (Rystiggo) market, 2021 - 2033 (USD Million)
  • Fig. 67 Saudi Arabia country dynamics
  • Fig. 68 Saudi Arabia Rozanolixizumab (Rystiggo) market, 2021 - 2033 (USD Million)
  • Fig. 69 UAE country dynamics
  • Fig. 70 UAE Rozanolixizumab (Rystiggo) market, 2021 - 2033 (USD Million)
  • Fig. 71 Kuwait country dynamics
  • Fig. 72 Kuwait Rozanolixizumab (Rystiggo) market, 2021 - 2033 (USD Million)
  • Fig. 73 Company categorization
  • Fig. 74 Company market position analysis
  • Fig. 75 Strategic framework